磷酸奥司他韦联合喜炎平治疗甲型流感的效果
|
摘要
目的观察磷酸奥司他韦联合喜炎平注射液治疗甲型流行性感冒(甲型流感)的临床效果和安全性。方法将2016年1月-2017年12月在中山市三角医院确诊并接受治疗的60例甲型流感患者随机分为对照组和联合组各30例,其中对照组给予磷酸奥司他韦治疗,联合组给予磷酸奥司他韦联合喜炎平注射液治疗。比较两组患者的治疗效果、主要症状和体征消失时间以及治疗期间不良反应发生情况。结果对照组治疗总有效率为63.33%,低于联合组的90.00%,差异有统计学意义(P<0.05);联合组患者发热、鼻塞/流涕消失时间及住院时间均明显短于对照组,差异有统计学意义(P<0.05),而咳嗽咳痰及扁桃体红肿消失时间与对照组差异无统计学意义(P>0.05);治疗期间对照组不良反应发生率为16.67%,联合组为13.33%,差异无统计学意义(P>0.05)。结论磷酸奥司他韦联合喜炎平治疗甲型流感效果明显,其可快速且有效地缓解患者的病情,且安全性高,值得临床推广应用。
Objective To observe the clinical efficacy and safety of oseltamivir phosphate combined with Xiyanping injection in the treatment of Influenza A. Methods 60 cases of influenza A diagnosed and treated in Zhongshan Triangle Hospital from January 2016 to December 2017 were selected and randomly divided into the control group and the combination group with 30 cases in each group. The patients in the control group were given oseltamivir phosphate treatment,the patients in the combination group were given oseltamivir phosphate combined with Xiyanping injection. The treatment effect,the disappearance time of the main symptoms and the signs and the occurrence of adverse reactions during the treatment were compared between the two groups. Results The control group's total effective rate was 63.33%,which was lower than90.00% of the combination group,the difference was statistically significant(P <0.05). The disappearance time of fever and nasal obstruction/runny nose and length of stay of the combination group were shorter than those of the control group,the differences were statistically significant(P<0.05). There was no statistically significant difference of the disappeared time of cough and expectoration and tonsil swelling between the two groups(P>0.05). During the treatment,the control group adverse reaction rate was 16.67%,the combination group was 13.33%,the difference was not statistically significant(P >0.05). Conclusion Oseltamivir phosphate combined with Xiyanping treatment of influenza A have a significant effect,which can quickly and effectively alleviate the patient's condition,and it is high safety and worthy of clinical application.
Objective To observe the clinical efficacy and safety of oseltamivir phosphate combined with Xiyanping injection in the treatment of Influenza A. Methods 60 cases of influenza A diagnosed and treated in Zhongshan Triangle Hospital from January 2016 to December 2017 were selected and randomly divided into the control group and the combination group with 30 cases in each group. The patients in the control group were given oseltamivir phosphate treatment,the patients in the combination group were given oseltamivir phosphate combined with Xiyanping injection. The treatment effect,the disappearance time of the main symptoms and the signs and the occurrence of adverse reactions during the treatment were compared between the two groups. Results The control group's total effective rate was 63.33%,which was lower than90.00% of the combination group,the difference was statistically significant(P <0.05). The disappearance time of fever and nasal obstruction/runny nose and length of stay of the combination group were shorter than those of the control group,the differences were statistically significant(P<0.05). There was no statistically significant difference of the disappeared time of cough and expectoration and tonsil swelling between the two groups(P>0.05). During the treatment,the control group adverse reaction rate was 16.67%,the combination group was 13.33%,the difference was not statistically significant(P >0.05). Conclusion Oseltamivir phosphate combined with Xiyanping treatment of influenza A have a significant effect,which can quickly and effectively alleviate the patient's condition,and it is high safety and worthy of clinical application.
引文
[1]汪艳,戴玉柱,崔大伟,等.2010-2013年杭州地区甲型流感H3N2分子流行病学分析[J].中国微生态学杂志,2016,28(10):1133-1137.
[2]车飞虎,崔大伟,孙海燕,等.2013-2015年浙江地区新型甲型H1N1流行性感冒的流行病学和临床特征调查[J].临床检验杂志,2016,34(4):307-311.
[3]王丽君,孙娜,刘慧,等.磷酸奥司他韦治疗儿童甲型H1N1流感的有效性和安全性分析[J].药物不良反应杂志,2017,19(3):178-181.
[4]卫生部流行性感冒诊断与治疗指南编撰专家组.流行性感冒诊断与治疗指南(2011年版)[J].中华结核和呼吸杂志,2011,9(10):66-74.
[5]刘红,徐瑞芳.磷酸奥司他韦联合抗病毒口服液治疗甲型H1N1流感的临床观察[J].中国中医急症,2017,26(8):1474-1476.
[6]蒋春颖,陈圣洁.磷酸奥司他韦联合炎琥宁治疗儿童甲型流行性感冒的疗效观察[J].临床合理用药杂志,2017, 10(26):17-18.
[7]孙海燕,童海江,崔大伟.2013-2015年浙江地区人感染H7N9禽流感病毒蛋白关键位点分析特征分析[J].中华临床感染病杂志,2016,9(4):330-335.
[8]王婷.喜炎平与复方氨酚烷胺治疗甲型H1N1流感的临床疗效比较[D].宁夏医科大学,2016.
[2]车飞虎,崔大伟,孙海燕,等.2013-2015年浙江地区新型甲型H1N1流行性感冒的流行病学和临床特征调查[J].临床检验杂志,2016,34(4):307-311.
[3]王丽君,孙娜,刘慧,等.磷酸奥司他韦治疗儿童甲型H1N1流感的有效性和安全性分析[J].药物不良反应杂志,2017,19(3):178-181.
[4]卫生部流行性感冒诊断与治疗指南编撰专家组.流行性感冒诊断与治疗指南(2011年版)[J].中华结核和呼吸杂志,2011,9(10):66-74.
[5]刘红,徐瑞芳.磷酸奥司他韦联合抗病毒口服液治疗甲型H1N1流感的临床观察[J].中国中医急症,2017,26(8):1474-1476.
[6]蒋春颖,陈圣洁.磷酸奥司他韦联合炎琥宁治疗儿童甲型流行性感冒的疗效观察[J].临床合理用药杂志,2017, 10(26):17-18.
[7]孙海燕,童海江,崔大伟.2013-2015年浙江地区人感染H7N9禽流感病毒蛋白关键位点分析特征分析[J].中华临床感染病杂志,2016,9(4):330-335.
[8]王婷.喜炎平与复方氨酚烷胺治疗甲型H1N1流感的临床疗效比较[D].宁夏医科大学,2016.